We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Cronos Australia is a drug manufacturers-specialty & generic business based in Australia. Cronos Australia shares (CAU) are listed on the Australian Securities Exchange (ASX) and all prices are in Australian dollars. Cronos Australia has a trailing 12-month revenue of around $21.7 million. If you're looking to buy shares, check out the steps below.
Our top pick for
US stocks
Our top pick for
Best overall broker
Our top pick for
Best low-cost broker
| 52-week range | $0.105 - $0.3975 |
|---|---|
| 50-day moving average | $0.2769 |
| 200-day moving average | $0.2462 |
| Target price | N/A |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.007 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the last close of A$0.24
| 1 week (2022-06-17) | -7.69% |
|---|---|
| 1 month (2022-05-26) | -11.11% |
| 3 months (2022-03-25) | -17.24% |
| 6 months (2021-12-24) | 18.52% |
| 1 year (2021-06-25) | 128.57% |
|---|---|
| 2 years (2020-06-26) | 211.69% |
Valuing Cronos Australia stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Cronos Australia's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Cronos Australia's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $590,966 (£333,036).
The EBITDA is a measure of a Cronos Australia's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $21.7 million |
|---|---|
| Operating margin TTM | 2.49% |
| Gross profit TTM | $872,928 |
| Return on assets TTM | 1.36% |
| Return on equity TTM | -6.65% |
| Profit margin | -4.34% |
| Book value | 0.039 |
| Market capitalisation | $134.9 million |
TTM: trailing 12 months
We're not expecting Cronos Australia to pay a dividend over the next 12 months.
Over the last 12 months, Cronos Australia's shares have ranged in value from as little as $0.105 up to $0.3975. A popular way to gauge a stock's volatility is its "beta".
Beta measures a share's volatility in relation to the market. The market (AU average) beta is 1, while Cronos Australia's is 1.3072. This would suggest that Cronos Australia's shares are more volatile than the average for this exchange and represent, relatively speaking, a higher risk (but potentially also market-beating returns).
Cronos Australia Limited operates as a medicinal cannabis company in Australia and Asia. It operates through three segments: Medical, Clinics, and Consumer. The company distributes PEACE NATURALS brand medicinal cannabis products; develops and sells medicinal cannabis products under the Adaya brand; and operates medicinal cannabis clinics. It also offers hemp seed oil personal care consumer products under the Bathing Shed brand; premium personal care products under the Saiph brand; and consumer CBD performance products under the FCTR brand. The company was incorporated in 2018 and is based in South Yarra, Australia.
Steps to owning and managing Arcadia Minerals shares.
Steps to owning and managing Nexgen Energy shares.
Steps to owning and managing Keypath Education shares.
If you want to directly fund climate solutions a green bond is a great place to start. Here is how they work.
What's the best way to invest money in Australia? Find out about robo advisors, index funds, cryptocurrency and more in this guide.
Steps to owning and managing EBR Systems shares.
Steps to owning and managing 5E Advanced Materials shares.
Steps to owning and managing Leo lithium shares.
Steps to owning and managing Besra Gold shares.
Steps to owning and managing The Lottery Corporation shares.
